In patent litigation between branded and generic manufacturers of canine flea & tick products, CRA was asked to assess irreparable harm. CRA examined effects from the entry and ongoing sales of the generic products, business losses suffered by the branded manufacturer and whether they could be attributed to the sale of the generic products, the influence of new channels, such as the internet, and the impact of newer, more effective classes of parasiticides. CRA submitted a declaration on irreparable harm.
Anticompetitive conduct and patents listed in the Orange Book
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...